Casey M Rebholz1, Morgan E Grams2, Kunihiro Matsushita3, Lesley A Inker4, Meredith C Foster4, Andrew S Levey4, Elizabeth Selvin5, Josef Coresh5. 1. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; crebhol1@jhu.edu. 2. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; Divisions of Nephrology and. 3. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 4. Division of Nephrology, Department of Medicine, Tufts Medical Center, Boston, Massachusetts. 5. Department of Epidemiology and Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland; and.
Abstract
BACKGROUND AND OBJECTIVES: Kidney disease progression, assessed by change in eGFR on the basis of creatinine, is an independent risk factor for cardiovascular disease and death. This study aimed to evaluate whether changes in multiple filtration markers, individually and combined, were associated with cardiovascular disease and death. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Creatinine, cystatin C, and β2-microglobulin were measured among 9716 Atherosclerosis Risk in Communities Study participants in 1990-1992 and 1996-1998. Percentage change in three filtration markers (eGFR on the basis of creatinine, eGFR on the basis of cystatin C, and 1/β2-microglobulin) individually and the average of percentage change across all three filtration markers were calculated. Cardiovascular events and deaths were ascertained from 1996 to 2011. Cox regression models were adjusted for established risk factors for cardiovascular disease and mortality and first measurement of eGFR on the basis of creatinine. RESULTS: During a median follow-up of 14 years, there were 1922 cardiovascular events and 2285 deaths from any cause. Decline of >30% in each filtration marker was significantly associated with higher risk of mortality compared with stable kidney function (-9.9% to +9.9% change in the filtration marker) with hazard ratios (95% confidence intervals) of 1.91 (1.67 to 2.18) for eGFR on the basis of creatinine, 2.29 (1.99 to 2.63) for eGFR on the basis of cystatin C, and 2.48 (2.15 to 2.86) for 1/β2-microglobulin, with similar associations for cardiovascular disease. An average decline of >30% across the three markers was strongly associated with higher risk of all-cause mortality (hazard ratio, 2.82; 95% confidence interval, 2.42 to 3.29). CONCLUSIONS: Kidney disease progression was assessed using >30% decline in eGFR on the basis of creatinine, eGFR on the basis of cystatin C, and 1/β2-microglobulin and average decline of >30% across the three filtration markers is strongly associated with risk of cardiovascular disease and death.
BACKGROUND AND OBJECTIVES:Kidney disease progression, assessed by change in eGFR on the basis of creatinine, is an independent risk factor for cardiovascular disease and death. This study aimed to evaluate whether changes in multiple filtration markers, individually and combined, were associated with cardiovascular disease and death. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Creatinine, cystatin C, and β2-microglobulin were measured among 9716 Atherosclerosis Risk in Communities Study participants in 1990-1992 and 1996-1998. Percentage change in three filtration markers (eGFR on the basis of creatinine, eGFR on the basis of cystatin C, and 1/β2-microglobulin) individually and the average of percentage change across all three filtration markers were calculated. Cardiovascular events and deaths were ascertained from 1996 to 2011. Cox regression models were adjusted for established risk factors for cardiovascular disease and mortality and first measurement of eGFR on the basis of creatinine. RESULTS: During a median follow-up of 14 years, there were 1922 cardiovascular events and 2285 deaths from any cause. Decline of >30% in each filtration marker was significantly associated with higher risk of mortality compared with stable kidney function (-9.9% to +9.9% change in the filtration marker) with hazard ratios (95% confidence intervals) of 1.91 (1.67 to 2.18) for eGFR on the basis of creatinine, 2.29 (1.99 to 2.63) for eGFR on the basis of cystatin C, and 2.48 (2.15 to 2.86) for 1/β2-microglobulin, with similar associations for cardiovascular disease. An average decline of >30% across the three markers was strongly associated with higher risk of all-cause mortality (hazard ratio, 2.82; 95% confidence interval, 2.42 to 3.29). CONCLUSIONS:Kidney disease progression was assessed using >30% decline in eGFR on the basis of creatinine, eGFR on the basis of cystatin C, and 1/β2-microglobulin and average decline of >30% across the three filtration markers is strongly associated with risk of cardiovascular disease and death.
Authors: Kunihiro Matsushita; Elizabeth Selvin; Lori D Bash; Nora Franceschini; Brad C Astor; Josef Coresh Journal: J Am Soc Nephrol Date: 2009-11-05 Impact factor: 10.121
Authors: Carmen A Peralta; Michael G Shlipak; Suzanne Judd; Mary Cushman; William McClellan; Neil A Zakai; Monika M Safford; Xiao Zhang; Paul Muntner; David Warnock Journal: JAMA Date: 2011-04-11 Impact factor: 56.272
Authors: Ziyad Al-Aly; Angelique Zeringue; John Fu; Michael I Rauchman; Jay R McDonald; Tarek M El-Achkar; Sumitra Balasubramanian; Diana Nurutdinova; Hong Xian; Kevin Stroupe; Kevin C Abbott; Seth Eisen Journal: J Am Soc Nephrol Date: 2010-10-14 Impact factor: 10.121
Authors: Guruprasad Manjunath; Hocine Tighiouart; Hassan Ibrahim; Bonnie MacLeod; Deeb N Salem; John L Griffith; Josef Coresh; Andrew S Levey; Mark J Sarnak Journal: J Am Coll Cardiol Date: 2003-01-01 Impact factor: 24.094
Authors: Michael G Shlipak; Ronit Katz; Bryan Kestenbaum; David Siscovick; Linda Fried; Anne Newman; Dena Rifkin; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2009-11-05 Impact factor: 10.121
Authors: Dena E Rifkin; Michael G Shlipak; Ronit Katz; Linda F Fried; David Siscovick; Michel Chonchol; Anne B Newman; Mark J Sarnak Journal: Arch Intern Med Date: 2008-11-10
Authors: Carmen A Peralta; Ronit Katz; Mark J Sarnak; Joachim Ix; Linda F Fried; Ian De Boer; Walter Palmas; David Siscovick; Andrew S Levey; Michael G Shlipak Journal: J Am Soc Nephrol Date: 2010-12-16 Impact factor: 14.978
Authors: Bharath Ambale-Venkatesh; Xiaoying Yang; Colin O Wu; Kiang Liu; W Gregory Hundley; Robyn McClelland; Antoinette S Gomes; Aaron R Folsom; Steven Shea; Eliseo Guallar; David A Bluemke; João A C Lima Journal: Circ Res Date: 2017-08-09 Impact factor: 17.367
Authors: Casey M Rebholz; Lesley A Inker; Yuan Chen; Menglu Liang; Meredith C Foster; John H Eckfeldt; Paul L Kimmel; Ramachandran S Vasan; Harold I Feldman; Mark J Sarnak; Chi-Yuan Hsu; Andrew S Levey; Josef Coresh Journal: Am J Kidney Dis Date: 2017-06-23 Impact factor: 8.860
Authors: Jordana B Cohen; Wei Yang; Liang Li; Xiaoming Zhang; Zihe Zheng; Paula Orlandi; Nisha Bansal; Rajat Deo; James P Lash; Mahboob Rahman; Jiang He; Tariq Shafi; Jing Chen; Debbie L Cohen; Kunihiro Matsushita; Michael G Shlipak; Myles Wolf; Alan S Go; Harold I Feldman Journal: Am J Kidney Dis Date: 2021-05-28 Impact factor: 8.860
Authors: Saaket Agrawal; Marcus D R Klarqvist; Connor Emdin; Aniruddh P Patel; Manish D Paranjpe; Patrick T Ellinor; Anthony Philippakis; Kenney Ng; Puneet Batra; Amit V Khera Journal: Patterns (N Y) Date: 2021-10-04